In-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticals
In-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticals
对Apellis Pharmicals的14项分析师建议的深入研究
In the latest quarter, 14 analysts provided ratings for Apellis Pharmaceuticals (NASDAQ:APLS), showcasing a mix of bullish and bearish perspectives.
在最近一个季度中，14位分析师为Apellis Pharmicals（纳斯达克股票代码：APLS）提供了评级，显示了看涨和看跌的混合前景。
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
下表简要介绍了他们最近的评级，展示了过去30天情绪的演变，并将其与前几个月进行了比较。
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $77.14, with a high estimate of $92.00 and a low estimate of $52.00. This upward trend is apparent, with the current average reflecting a 12.2% increase from the previous average price target of $68.75.
分析师对12个月目标股价的评估提供了更多见解，显示平均目标价为77.14美元，最高估计为92.00美元，低估值为52.00美元。这种上升趋势显而易见，当前的平均价格较之前的68.75美元的平均目标股价上涨了12.2％。
Exploring Analyst Ratings: An In-Depth Overview
探索分析师评级：深入概述
An in-depth analysis...
对分析师...
登录免费看全文
登录/注册